丸美生物(603983) - 2025 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2025 reached ¥3,459,318,084, representing a 16.48% increase compared to ¥2,969,770,566.54 in 2024[22] - The total profit for 2025 was ¥295,731,444.58, a decrease of 22.31% from ¥380,656,508.96 in 2024[22] - The net profit attributable to shareholders for 2025 was ¥247,239,140.99, down 27.63% from ¥341,628,707.73 in 2024[22] - The basic earnings per share for 2025 was ¥0.62, a decline of 27.06% compared to ¥0.85 in 2024[23] - The total assets at the end of 2025 were ¥4,613,454,827.03, reflecting an 8.87% decrease from ¥5,062,564,094.81 at the end of 2024[22] - The net cash flow from operating activities for 2025 was ¥273,876,402.32, which is an 8.87% decrease from ¥300,526,858.35 in 2024[22] - The weighted average return on equity for 2025 was 7.28%, down 2.80 percentage points from 10.08% in 2024[23] - The company's net assets attributable to shareholders at the end of 2025 were ¥3,331,157,901.88, a slight decrease of 1.46% from ¥3,380,406,892.85 at the end of 2024[22] Revenue and Sales - The company achieved a total revenue of 3.459 billion RMB in the reporting period, representing a year-on-year increase of 16.48%[35] - The "Marubi" brand generated revenue of 2.547 billion RMB, up 23.94% year-on-year, while the "Lianhuo" brand's revenue remained stable at 906 million RMB[35] - The online channel generated revenue of 3.059 billion yuan, accounting for 88.56% of total revenue, with a year-on-year growth of 20.42%[47] - The offline channel reported revenue of 395 million yuan, representing 11.44% of total revenue, with a year-on-year decline of 7.46%[47] Expenses and Costs - Sales expenses rose to 2.057 billion RMB, a 25.8% increase year-on-year, primarily due to high online traffic and promotion costs[35] - Management expenses increased to 161 million RMB, up 48.36% year-on-year, mainly due to depreciation and amortization costs associated with the completion of the Marubi building[35] - The cost of goods sold increased to ¥889,519,268.27, up 13.89% compared to ¥781,028,905.06 in the previous year, primarily due to the growth in operating revenue[62] - Total cost for the period reached CNY 879,807,522.48, an increase of 12.70% compared to CNY 780,636,097.52 in the previous year[68] Research and Development - Research and development expenses amounted to 85.3716 million RMB, reflecting a year-on-year growth of 16.08% as the company continues to invest in R&D[35] - The company achieved significant progress in the field of recombinant functional proteins, successfully developing 13 new recombinant proteins and advancing them to pilot testing[39] - The company has enriched its proprietary raw material library with 13 new self-developed raw materials, enhancing its innovation capabilities[40] - The company applied for 92 new patents during the reporting period, bringing the total to 686, with 388 patents granted, including 273 invention patents[42] Market Position and Strategy - The company operates in the chemical raw materials and chemical products manufacturing industry, with a focus on cosmetics[32] - The cosmetics sector's retail sales in China reached 465.3 billion RMB in 2025, growing by 5.1% year-on-year[34] - The company’s market position in the domestic cosmetics market remains strong, with the main brand "MARUBI" recognized as a leading brand in the mid-to-high-end segment[85] - The company plans to expand its market presence and enhance its product offerings in response to evolving industry regulations and consumer demands[82] Marketing and Brand Development - The company’s marketing activities achieved over 1.8 billion exposures through various campaigns, enhancing brand visibility and credibility[45] - The company launched the "Marubi Little Gold Needle Super Mask," which quickly topped the Douyin mask ranking, driven by effective marketing strategies[45] - The marketing strategy emphasizes innovative campaigns that combine scientific communication, emotional resonance, and cultural empowerment to strengthen brand trust[110] Corporate Governance - The company has established a sound governance structure, ensuring clear responsibilities and decision-making processes among its various levels of management[117] - The company received a Wind ESG AA rating, reflecting its commitment to sustainable development practices[121] - The company actively engages in investor relations, holding regular performance briefings after each financial report release[121] - The company has established a dedicated committee structure within the board, including audit, compensation, and nomination committees, with independent directors in key roles[119] Employee Development and Compensation - The company has established a dual career development pathway for employees, focusing on "collaborative ability" and "innovation literacy" to enhance organizational capabilities[58] - The company has trained over 130 managers through various development programs during the reporting period[58] - The company has a comprehensive compensation and benefits system, ensuring employee rights and sharing the results of corporate development[140] Stock and Financial Management - The company plans to implement stock price stabilization measures, including profit distribution or capital increase, stock buybacks, and stock purchases by major shareholders[161] - The company will announce a stock buyback plan within 10 trading days after triggering the stock price stabilization measures, detailing the number of shares, price range, and funding sources[162] - The company will implement stock buyback measures a maximum of twice within a single accounting year[161] Compliance and Legal Matters - The company has not faced any delisting risks or bankruptcy restructuring issues during the reporting period[173] - The company has taken proactive measures to address any issues raised by regulatory bodies, demonstrating a commitment to governance and compliance[173] - The company has maintained transparency in disclosing all related party transactions, with no undisclosed transactions reported[169]